AU769482B2 - Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction - Google Patents

Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction Download PDF

Info

Publication number
AU769482B2
AU769482B2 AU77792/00A AU7779200A AU769482B2 AU 769482 B2 AU769482 B2 AU 769482B2 AU 77792/00 A AU77792/00 A AU 77792/00A AU 7779200 A AU7779200 A AU 7779200A AU 769482 B2 AU769482 B2 AU 769482B2
Authority
AU
Australia
Prior art keywords
lhrh antagonist
short
contraceptive
induction treatment
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU77792/00A
Other languages
English (en)
Other versions
AU7779200A (en
Inventor
Klaus Diedrich
Jurgen Engel
Ricardo Felberbaum
Wolfgang Kupker
Hilde Riethmuller-Winzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of AU7779200A publication Critical patent/AU7779200A/en
Application granted granted Critical
Publication of AU769482B2 publication Critical patent/AU769482B2/en
Assigned to ZENTARIS GMBH reassignment ZENTARIS GMBH Amend patent request/document other than specification (104) Assignors: ZENTARIS AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU77792/00A 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction Ceased AU769482B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23
US60/155478 1999-09-23
PCT/EP2000/009212 WO2001021194A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction

Publications (2)

Publication Number Publication Date
AU7779200A AU7779200A (en) 2001-04-24
AU769482B2 true AU769482B2 (en) 2004-01-29

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77792/00A Ceased AU769482B2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction

Country Status (22)

Country Link
EP (1) EP1214086A2 (enExample)
JP (2) JP2003509467A (enExample)
KR (1) KR100772852B1 (enExample)
CN (2) CN101045155A (enExample)
AU (1) AU769482B2 (enExample)
BG (1) BG66128B1 (enExample)
BR (1) BR0014198A (enExample)
CA (1) CA2383510A1 (enExample)
HK (1) HK1049117A1 (enExample)
HU (1) HUP0202741A3 (enExample)
IL (1) IL148185A0 (enExample)
MX (1) MXPA02002436A (enExample)
NO (1) NO331198B1 (enExample)
NZ (1) NZ534836A (enExample)
PL (1) PL201898B1 (enExample)
RU (1) RU2255759C2 (enExample)
SK (1) SK3752002A3 (enExample)
TR (1) TR200200738T2 (enExample)
TW (1) TWI267373B (enExample)
UA (1) UA73956C2 (enExample)
WO (1) WO2001021194A2 (enExample)
ZA (1) ZA200201374B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
ES2633453T3 (es) 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
WO2010085145A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
MX2020001877A (es) 2017-08-18 2020-09-14 Abbvie Inc Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
WO2019036713A1 (en) 2017-08-18 2019-02-21 Abbvie Inc. SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
BR112020021276A2 (pt) 2018-04-19 2021-01-26 Abbvie Inc. métodos de tratamento de sangramento menstrual intenso
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027863A1 (de) * 1996-01-29 1997-08-07 Schering Aktiengesellschaft Pharmazeutisches kombinationspräparat aus lhrh-analoga und antiöstrogenen zur behandlung von gynäcologischen störungen
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
DE69515666T2 (de) * 1994-07-22 2000-07-06 Medical College Of Hampton Roads, Norfolk VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
RU2108583C1 (ru) * 1996-07-29 1998-04-10 Николай Владимирович Рымашевский Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
WO1997027863A1 (de) * 1996-01-29 1997-08-07 Schering Aktiengesellschaft Pharmazeutisches kombinationspräparat aus lhrh-analoga und antiöstrogenen zur behandlung von gynäcologischen störungen
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
AU7779200A (en) 2001-04-24
EP1214086A2 (en) 2002-06-19
JP2003509467A (ja) 2003-03-11
HK1049117A1 (zh) 2003-05-02
CN101045155A (zh) 2007-10-03
HUP0202741A2 (hu) 2003-01-28
CN1376070A (zh) 2002-10-23
ZA200201374B (en) 2002-10-30
TWI267373B (en) 2006-12-01
MXPA02002436A (es) 2003-02-12
JP2012051920A (ja) 2012-03-15
KR20020035879A (ko) 2002-05-15
NO331198B1 (no) 2011-10-31
KR100772852B1 (ko) 2007-11-02
CA2383510A1 (en) 2001-03-29
IL148185A0 (en) 2002-09-12
PL201898B1 (pl) 2009-05-29
NO20021430L (no) 2002-05-07
PL353244A1 (en) 2003-11-03
BG66128B1 (bg) 2011-06-30
TR200200738T2 (tr) 2002-08-21
WO2001021194A3 (en) 2002-03-14
SK3752002A3 (en) 2003-06-03
WO2001021194A2 (en) 2001-03-29
BR0014198A (pt) 2002-05-21
HUP0202741A3 (en) 2003-12-29
NZ534836A (en) 2007-07-27
UA73956C2 (en) 2005-10-17
BG106584A (bg) 2003-02-28
RU2255759C2 (ru) 2005-07-10
NO20021430D0 (no) 2002-03-21

Similar Documents

Publication Publication Date Title
Erkkola et al. Role of progestins in contraception
JP3130048B2 (ja) エストロゲン依存症の治療
JP2012051920A (ja) 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用
US20120015917A1 (en) Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy
Bedaiwy et al. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists
TW577735B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
US20080255053A1 (en) Method for the therapeutic management of endometriosis
La Marca et al. Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply
ES2293215T3 (es) Uso de una combinacion de un inhibidor de aromatasa, un progestageno y un estrogeno para el tratamiento de endometriosis.
BG63363B1 (bg) Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания
JP3925688B2 (ja) ＧｎＲＨａ治療中および／またはＧｎＲＨａ治療後の副作用を治療するための製薬学的調剤
BR112020021565A2 (pt) Composição para tratamento de uma ou mais doenças relacionadas com estrogênio
Gunasheela Medical Treatment of Endometriosis
Patel 6 Hysteroscopic Implications
HK1107262A (en) Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
JP2007197459A (ja) 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: ZENTARIS GMBH

Free format text: FORMER NAME: ZENTARIS AG

FGA Letters patent sealed or granted (standard patent)